Plain-English translation of NCT06598449 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing for very young babies (ages 12–23 months) who have Dravet syndrome, a rare genetic epilepsy that causes frequent, serious seizures. has already been approved and shown to work well in children 2 years and older with this condition, reducing seizures by about 75% in some children. This study wants to see if the medication is safe to use in babies under 2 years old.
Dravet syndrome is a severe form of epilepsy that typically starts in a baby's first year of life and is caused by a genetic change. Many common seizure medications actually make seizures worse in babies with this condition, leaving families with very limited treatment options. This medication has shown promise in older children, and doctors want to know if it can safely help younger babies too.
You likely qualify if…
You likely don't qualify if…
Your child would take the medication twice a day by mouth at home, with doses spaced 8–12 hours apart. The dose is based on your child's weight and will be gradually adjusted. Before starting, your child will need a heart ultrasound (echocardiogram) to make sure their heart is healthy. Your doctor will monitor your child's seizures and health throughout the study to make sure the medication is working and safe.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States